-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
We increase our target price to $76 from $66, on a forward P/E of 46x our 2027 EPS projection of $1.65. We raise our 2026 EPS view to $1.39 from $1.16 and adjust our 2027 forecast to $1.65 from $1.47. Q1 2025 revenue rose 24% Y/Y to $268M, ahead of expectations, driven by broad-based strength across end markets and geographies. On the profitability front, adjusted gross margin expanded 420 bps to 71.8% and adjusted EBITDA margin of 26.9% exceeded guidance by over 600 bps, reflecting cost discipline and execution. Management remains focused on efficiency initiatives, making further progress toward achieving its $35M to $40M annualized net cost savings target by the end of the year, and we see a path to sustained double-digit EPS growth in the near term. Innovations (In-Sight 6900 and In-Sight 3900) announced during the quarter, positioning CGNX as a leading provider of AI-powered machine vision technologies.